美国临床肿瘤学会（ASCO）年会是全球最大的肿瘤会议，去年已有4万余人参加。2023 ASCO年会将于当地时间6月2～6日在美国芝加哥举行。ASCO会议官网已公布了此次年会的日程和摘要题目，肿瘤瞭望带您提前速览泌尿肿瘤领域的重磅口头报告及中国内地研究进展，共同探讨尖端科学研究和治疗进展（如有遗漏和不妥之处，欢迎留言补充）。
编者按：美国临床肿瘤学会（ASCO）年会是全球最大的肿瘤会议，去年已有4万余人参加。2023 ASCO年会将于当地时间6月2～6日在美国芝加哥举行。ASCO会议官网已公布了此次年会的日程和摘要题目，肿瘤瞭望带您提前速览泌尿肿瘤领域的重磅口头报告及中国内地研究进展，共同探讨尖端科学研究和治疗进展（如有遗漏和不妥之处，欢迎留言补充）。
01
6月4日——Oral Abstract Session
Clinical Science Symposium
摘要号：LBA104
Effect of CBM588 in combination with cabozantinib plus nivolumab for patients(pts)with metastatic renal cell carcinoma(mRCC):A randomized clinical trial.
CBM588联合卡博替尼及纳武单抗治疗转移性肾细胞癌（mRCC）：一项随机临床试验
讲者：Hedyeh Ebrahimi，MD，MPH|City of Hope Comprehensive Cancer Center
Genitourinary Cancer—Prostate，Testicular，and Penile
摘要号：LBA5000
Prostate irradiation in men with de novo，low-volume，metastatic，castration-sensitive prostate cancer(mCSPC):Results of PEACE-1，a phase 3 randomized trial with a 2x2 design.
新发、低体积、转移性、去势敏感性前列腺癌（mCSPC）的放射治疗：2x2设计的Ⅲ期随机临床试验PEACE-1研究结果
讲者：Alberto Bossi，MD|Department of Radiation Oncology，Institute Gustave Roussy
摘要号：5001
Development and validation of an AI-derived digital pathology-based biomarker to predict benefit of long-term androgen deprivation therapy with radiotherapy in men with localized high-risk prostate cancer across multiple phase III NRG/RTOG trials.
基于AI的数字病理学生物标志物可预测Ⅲ期NRG/RTOG试验中的局部高危前列腺癌长期雄激素剥夺疗法与放疗的获益情况
讲者：Andrew J.Armstrong，MD|Duke Cancer Institute Center for Prostate&Urologic Cancers
摘要号：5002
Prognostic impact of PSA nadir(n)≥0.1 ng/mL within 6 months(m)after completion of radiotherapy(RT)for localized prostate cancer(PCa):An individual patient-data(IPD)analysis of randomized trials from the ICECAP collaborative.
放疗后6个月内PSA最低值≥0.1 ng/mL对局限性前列腺癌（PCa）的预后影响：ICECAP合作随机性试验的个体患者数据分析
讲者：Praful Ravi，MRCP，MBBChir|Dana-Farber Cancer Institute
摘要号：5003
Presence of somatic/germline homologous recombination repair(HRR)mutations and outcomes in metastatic castration-resistant prostate cancer(mCRPC)patients(pts)receiving first?line(1L)treatment stratified by BRCA status.
根据BRCA分层，转移性去势抵抗性前列腺癌（mCRPC）患者一线治疗结局和体细胞/胚系同源重组修复突变存在分析
讲者：David Olmos，MD，PhD|Hospital Universitario 12 de Octubre.Instituto de Investigación Sanitaria Hospital 12 de Octubre
摘要号：5004
TALAPRO-2:Phase 3 study of talazoparib(TALA)+enzalutamide(ENZA)versus placebo(PBO)+ENZA as first-line(1L)treatment for patients(pts)with metastatic castration-resistant prostate cancer(mCRPC)harboring homologous recombination repair(HRR)gene alterations.
TALAPRO-2：他拉唑帕尼联合恩扎卢胺对比安慰剂联合恩扎卢胺一线治疗具有同源重组修复缺陷的转移性去势抵抗性前列腺癌（mCRPC）Ⅲ期研究
讲者：Karim Fizazi，MD|Institut Gustave Roussy，University of Paris-Saclay
摘要号：5005
LuPARP:Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer(mCRPC).
LuPARP：177Lu-PSMA-617和奥拉帕利治疗转移性去势抵抗性前列腺癌（mCRPC）的Ⅰ期试验分析
讲者：Shahneen Sandhu，MBBS，FRACP|Department of Medical Oncology，Peter MacCallum Cancer Centre;and Sir Peter MacCallum Department of Oncology，University of Melbourne
摘要号：5006
Long term follow-up analysis of plasma miR371 expression to detect early relapse in patients with clinical stage I testicular germ cell tumors on surveillance.
通过miR371表达的长期随访来分析Ⅰ期睾丸生殖细胞肿瘤的早期复发情况
讲者：Lucia Nappi，MD，PhD，FRCPC|Vancouver Prostate Centre，Department of Urologic Sciences，University of British Columbia
摘要号：5007
The genomic and transcriptomic landscapes of chemotherapy naïve vs post-chemotherapy germ cell tumors.
化疗初期与化疗后的生殖细胞肿瘤基因组和转录组图谱
讲者：Aditya Bagrodia，MD|University of California San Diego Health
摘要号：5008
Primary retroperitoneal lymph node dissection(RPLND)in seminoma stage IIA-IIC≤3cm:Combined results of the SWENOTECA(Swedish Norwegian Testicular Cancer Group)and Cologne.
原发性腹膜后淋巴结清扫术（RPLND）治疗ⅡA-ⅡC期≤3cm精原细胞瘤：SWENOTECA（瑞典挪威睾丸癌学组）和科隆研究的联合结果
讲者：Torgrim Tandstad，MD，PhD|St.Olav’s University Hospital
02
6月5日——Oral Abstract Session
Genitourinary Cancer—Kidney and Bladder
摘要号：LBA4500
Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor(ICI)treatment in metastatic renal cell carcinoma(RCC):Primary PFS analysis from the phase 3，randomized，open-label CONTACT-03 study.
既往经免疫检查点抑制剂（ICI）治疗进展后，阿替利珠单抗联合卡博替尼对比卡博替尼单药治疗转移性肾细胞癌（RCC）的疗效和安全性：Ⅲ期、随机、开放标签CONTACT-03研究的PFS分析
讲者：Toni K.Choueiri，MD|Dana-Farber Cancer Institute，Harvard Medical School
摘要号：LBA4501
Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma:5-year analysis of KEYNOTE-426.
帕博利珠单抗联合阿昔替尼对比舒尼替尼一线治疗晚期肾透明细胞癌：KEYNOTE-426的5年分析
讲者：Brian I.Rini，MD，FASCO|Vanderbilt-Ingram Cancer Center
摘要号：4502
Final prespecified overall survival(OS)analysis of CLEAR:4-year follow-up of lenvatinib plus pembrolizumab(L+P)vs sunitinib(S)in patients(pts)with advanced renal cell carcinoma(aRCC).
CLEAR预设的最终总生存期分析：仑伐替尼联合帕博利珠单抗对比舒尼替尼治疗晚期肾细胞癌（aRCC）的4年随访结果
讲者：Thomas E.Hutson，FACP|Texas Oncology
摘要号：4503
Overall survival(OS)by response to first-line(1L)induction treatment with atezolizumab(atezo)+platinum/gemcitabine(plt/gem)vs placebo+plt/gem in patients(pts)with metastatic urothelial carcinoma(mUC):Updated data from the IMvigor130 OS final analysis.
阿替利珠单抗联合铂类/吉西他滨对比安慰剂方案一线治疗转移性尿路上皮癌（mUC）的总生存期（OS）：IMvigor130 OS最终分析更新
讲者：Enrique Grande，MD|MD Anderson Cancer Center
摘要号：4504
Erdafitinib(ERDA)vs ERDA plus cetrelimab(ERDA+CET)for patients(pts)with metastatic urothelial carcinoma(mUC)and fibroblast growth factor receptor alterations(FGFRa):Final results from the phase 2 Norse study.
厄达替尼对比恩扎卢胺联合cetrelimab治疗转移性尿路上皮癌（mUC）和成纤维细胞生长因子受体改变（FGFRa）患者：Ⅱ期Norse研究的最终结果
讲者：Arlene O.Siefker-Radtke，MD|Department of Genitourinary Medical Oncology，The University of Texas MD Anderson Cancer Center
摘要号：4505
Study EV-103 dose escalation/cohort A:Long-term outcome of enfortumab vedotin+pembrolizumab in first-line(1L)cisplatin-ineligible locally advanced or metastatic urothelial carcinoma(la/mUC)with nearly 4 years of follow-up.
EV-103剂量递增/队列A研究：enfortumab vedotin联合帕博利珠单抗一线治疗顺铂不耐受的局部晚期或转移性尿路上皮癌（la/mUC）的长期结局
讲者：Shilpa Gupta，MD|Cleveland Clinic
摘要号：4506
Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy:Subgroup analyses from the phase 3 CheckMate 914(part A)trial.
纳武单抗联合伊匹木单抗对比安慰剂辅助治疗肾切除术后高复发风险的局限性肾细胞癌患者：Ⅲ期CheckMate 914试验亚组分析（队列A）
讲者：Robert J.Motzer，MD|Memorial Sloan Kettering Cancer Center
摘要号：LBA4507
Multicenter randomized phase III trial of dose-dense methotrexate，vinblastine，doxorubicin，and cisplatin(dd-MVAC)or gemcitabine and cisplatin(GC)as perioperative chemotherapy for muscle-invasive bladder cancer(MIBC):Overall survival(OS)data at 5 years in the GETUG/AFU V05 VESPER trial.
甲氨蝶呤、长春碱、多柔比星和顺铂剂量密集方案（dd-MVAC）或吉西他滨联合顺铂（GC）在围手术期治疗肌层浸润性膀胱癌（MIBC）的多中心随机Ⅲ期试验：GETUG/AFU V05 VESPER试验的5年总生存期分析
讲者：Christian Pfister，MD，PhD|Rouen University Hospital
摘要号：4508
SWOG S1011:A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer.
SWOG S1011：根治性膀胱切除术治疗肌层浸润性尿路上皮癌时，标准方案与扩大淋巴结切除术的Ⅲ期手术试验获益分析
讲者：Seth P.Lerner，MD|Baylor College of Medicine
Late-Breaking Abstract Session
摘要号：LBA4619
Phase 3 THOR study:Results of erdafitinib(erda)versus chemotherapy(chemo)in patients(pts)with advanced or metastatic urothelial cancer(mUC)with select fibroblast growth factor receptor alterations(FGFRalt).
Ⅲ期THOR研究：厄达替尼对比化疗方案治疗伴有特定成纤维细胞生长因子受体改变（FGFRalt）的晚期或转移性尿路上皮癌（mUC）结果
讲者：Yohann Loriot，MD，PhD|Department of Cancer Medicine，Gustave Roussy Institute，INSERM 981，University Paris-Saclay
摘要号：4521
Effect of KDR mutations on efficacy of immune checkpoint inhibitors in patients with bladder cancer.
KDR突变对膀胱癌患者免疫检查点抑制剂的疗效影响
讲者：戴洪海山东省立医院
摘要号：4533
Preliminary results from a phase II study comparing sunitinib alone or with stereotactic body radiotherapy(SBRT)for newly diagnosed oligometastatic renal cell carcinoma.
舒尼替尼单药或联合立体定向体部放疗（SBRT）治疗初诊为寡转移性肾细胞癌的Ⅱ期研究初步结果
讲者：刘洋中山大学肿瘤防治中心
摘要号：4543
Immunoglobulin as a predictive biomarker for the efficacy of immune checkpoint inhibitor combined with VEGF-TKI in metastatic renal cell carcinoma.
免疫球蛋白作为免疫检查点抑制剂联合VEGF-TKI治疗转移性肾细胞癌疗效的预测生物标志物
讲者：Honglei Cui中国医学科学院肿瘤医院
摘要号：4566
Disitamab vedotin，a novel humanized anti-HER2 antibody-drug conjugate(ADC)，combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma:An open-label phase 1b/2 study.
维迪西妥单抗联合特瑞普利单抗治疗局部晚期或转移性尿路上皮癌患者：一项开放标签Ⅰb/Ⅱ期研究
讲者：盛锡楠北京大学肿瘤医院
摘要号：4585
Final analysis results from a multicenter clinical study of tislelizumab combined with gemcitabine and cisplatin as neoadjuvant therapy in patients with cT2-T4aN0M0 MIBC.
替雷利珠单抗联合吉西他滨和顺铂新辅助治疗cT2-T4aN0M0 MIBC的多中心临床研究最终分析
讲者：林天歆中山大学孙逸仙纪念医院
摘要号：TPS4612
ALTER-UC-007:A prospective phase 2 study of anlotinib with gemcitabine and cisplatin or anlotinib with penpulimab as perioperative treatment for patients with muscle-invasive urothelial carcinoma(MIUC).
ALTER-UC-007：安罗替尼联合吉西他滨和顺铂或安罗替尼联合派安普利单抗围手术期治疗肌层浸润性尿路上皮癌（MIUC）的前瞻性Ⅱ期研究
讲者：张海梁复旦大学附属肿瘤医院
摘要号：5057
Tumor heterogeneity and treatment response assessment using next generation imaging and liquid biopsy in patients with metastatic castration resistant prostate cancer receiving abiraterone(ANGELA):A single-center prospective observational trial.
通过下一代成像和液体活检技术评估阿比特龙治疗转移性去势抵抗性前列腺癌患者的肿瘤异质性和治疗缓解情况：一项单中心前瞻性观察试验
讲者：朱耀复旦大学附属肿瘤医院
摘要号：5065
Deutenzalutamide，an oral deuterated androgen receptor inhibitor，vs placebo for patients with mCRPC who have experienced treatment failure with abiraterone and docetaxel:Results of the HC-1119-04 phase 3 trial.
Deutenzalutamide，一种口服氘代雄激素受体抑制剂，用于治疗经阿比特龙和多西紫杉醇治疗失败的mCRPC患者：HC-1119-04Ⅲ期试验结果
讲者：叶定伟复旦大学附属肿瘤医院
京公网安备 11010502033352号